A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\[7\]-2030\[6\]), including a multidisciplinary training program by the four leading international expert centers.
The PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.
Age 18 years or older
Pathology-confirmed (LAPC)*
CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy ([m]FOLFIRINOX / gemcitabine-nab-paclitaxel).
Metastatic pancreatic cancer prior to induction chemotherapy.
According to the Dutch Pancreatic Cancer Group (DPCG) definition: >90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either >270 degrees or occlusion.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead sponsor
UMC Utrecht
Collaborator
Erasmus Medical Center
Collaborator
Leiden University Medical Center
Collaborator
University Medical Center Groningen
Collaborator
Radboud University Medical Center
Collaborator
Maastricht University Medical Center
Collaborator
Medisch Spectrum Twente
Collaborator
Isala
Collaborator
Frisius Medisch Centrum
Collaborator
Onze Lieve Vrouwe Gasthuis
Collaborator
Amphia ziekenhuis
Collaborator
Jeroen Bosch Ziekenhuis
Collaborator
Catharina Ziekenhuis Eindhoven
Collaborator
University of Colorado, Denver
Collaborator
Heidelberg University
Collaborator
M.D. Anderson Cancer Center
Collaborator
NYU Langone Health
Collaborator
Dutch Cancer Society
Collaborator
Maag Lever Darm Stichting
Collaborator
Deltaplan Alvleesklierkanker
Collaborator